<!doctype html>
<html lang="en">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>How Is ResMed&#x27;s Stock Performance Compared to Other Healthcare Stocks? · Newsletter</title>
<style>
:root{--bg:#0f1221;--fg:#e8ecf3;--muted:#98a2b3;--link:#74b7ff;--card:#171b2f;--btn:#2563eb;--btnText:#fff;}
*{box-sizing:border-box} body{margin:0;font-family:ui-sans-serif,system-ui,-apple-system,Segoe UI,Roboto,Inter,Arial;background:var(--bg);color:var(--fg)}
.container{max-width:920px;margin:40px auto;padding:0 16px}
.header{display:flex;justify-content:space-between;align-items:center;gap:16px}
.brand{font-size:.95rem;font-weight:700;color:#8fb5ff}
.kicker{font-size:.85rem;color:var(--muted)}
.card{background:var(--card);border-radius:14px;padding:26px;margin-top:18px;box-shadow:0 6px 24px rgba(0,0,0,.35)}
h1{font-size:2rem;margin:.2rem 0 0}
.meta{font-size:.9rem;color:var(--muted);margin:.6rem 0 1rem}
ul{margin:12px 0 18px 22px;padding:0}
li{margin:.35rem 0;line-height:1.5}
a{color:var(--link);text-decoration:none}
a:hover{text-decoration:underline}
.btns{display:flex;gap:10px;margin-top:10px}
.btn{display:inline-block;background:transparent;border:1px solid #6b7280;color:#e5e7eb;padding:8px 12px;border-radius:8px;font-size:.9rem}
.btn.primary{background:var(--btn);border-color:var(--btn);color:var(--btnText)}
.footer{margin-top:26px;font-size:.8rem;color:var(--muted);text-align:center}
hr{border:0;border-top:1px solid #2a2f48;margin:18px 0}
</style>
<body>
  <div class="container">
    <div class="header">
      <div class="brand">Daily Finance Newsletter</div>
      <div class="kicker">5–7 key bullets per story</div>
    </div>

    <div class="card">
      <h1>How Is ResMed&#x27;s Stock Performance Compared to Other Healthcare Stocks?</h1>
      <div class="meta">2025-09-15 06:07:58+00:00 UTC</div>
      <ul>
        <li>Further, its non-GAAP EPS soared 22.6% year-over-year to $2.55, exceeding the consensus estimates by 3.7%.</li>
        <li>RMD’s mean price target of $289.25 suggests a 7.1% upside potential from current price levels.</li>
        <li>ResMed’s overall net revenues for the quarter grew 10.2% year-over-year to $1.35 billion, surpassing the Street expectations by 1.9%.</li>
        <li>22 and is currently trading 8.1% below that peak.</li>
        <li>ResMed’s stock prices gained 2.7% in the trading session following the release of its impressive Q4 results on Jul.</li>
        <li>Moreover, ResMed has also significantly outperformed its peer, Becton, Dickinson and Company’s (BDX) 17.6% decline in 2025 and 20.7% plunge over the past 52 weeks.</li>
        <li>RMD stock prices have surged 18.1% in 2025 and 7.8% over the past 52 weeks, outpacing XLV’s marginal 39 bps uptick on a YTD basis and 11.4% decline over the past year.</li>
      </ul>
      <div class="btns">
        <a class="btn" href="https://finance.yahoo.com/m/18e5adce-bfb3-30fe-a075-7f55ac01f1bc/how-is-resmed%27s-stock.html" target="_blank" rel="noopener nofollow">Original</a>
        <a class="btn primary" href="https://twitter.com/intent/tweet?text=How+Is+ResMed%27s+Stock+Performance+Compared+to+Other+Healthcare+Stocks%3F%0A%E2%80%A2+Further%2C+its+non-GAAP+EPS+soared+22.6%25+year-over-year+to+%242.55%2C+exceeding+the+consensus+estimates+by+3.7%25.%0A%E2%80%A2+RMD%E2%80%99s+mean+price+target+of+%24289.25+suggests+a+7.1%25+upside+potential+from%E2%80%A6%0Ahttps%3A%2F%2Ffinance.yahoo.com%2Fm%2F18e5adce-bfb3-30fe-a075-7f55ac01f1bc%2Fhow-is-resmed%2527s-stock.html" target="_blank" rel="noopener">Share on X</a>
      </div>
      <div class="footer">© 2025 · Built from digest_5bullets.md</div>
    </div>
  </div>
</body>
</html>
